Selpercatinib Receives Regular Approval for Non–Small Cell Lung Cancer
Selpercatinib was granted regular approval from the US FDA to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. A companion diagnostic test also was approved. Marketed as R...
Gespeichert in:
Veröffentlicht in: | JAMA : the journal of the American Medical Association 2022-11, Vol.328 (17), p.1679-1679 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Selpercatinib was granted regular approval from the US FDA to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. A companion diagnostic test also was approved. Marketed as Retevmo by Eli Lilly, selpercatinib is potent against a variety of cancer-causing RET protein alterations, including gene fusions. RET gene fusions drive 1% to 2% of NSCLCs and are responsible for an estimated 10,000 new cases annually worldwide. RET fusions are also found in 10% to 20% of papillary thyroid cancers as well as subgroups of colorectal, breast, and other cancers. |
---|---|
ISSN: | 0098-7484 1538-3598 |
DOI: | 10.1001/jama.2022.18445 |